Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred Tax AssetsCurrent Deferred Tax AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sagimet Biosciences (SGMT) Common Equity (2022 - 2026)

Sagimet Biosciences' Common Equity history spans 5 years, with the latest figure at $102.5 million for Q1 2026.

  • Quarterly Common Equity fell 26.28% to $102.5 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $102.5 million through Mar 2026, down 26.28% year-over-year, with the annual reading at $111.4 million for FY2025, 28.51% down from the prior year.
  • Common Equity came in at $102.5 million for Q1 2026, down from $111.4 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $190.0 million in Q1 2024 to a low of -$198.4 million in Q2 2023.
  • The 5-year median for Common Equity is $106.9 million (2025), against an average of $34.9 million.
  • Year-over-year, Common Equity surged 198.61% in 2024 and then crashed 30.13% in 2025.
  • Sagimet Biosciences' Common Equity stood at -$187.0 million in 2022, then skyrocketed by 148.71% to $91.1 million in 2023, then surged by 71.09% to $155.8 million in 2024, then fell by 28.51% to $111.4 million in 2025, then fell by 8.01% to $102.5 million in 2026.
  • Per Business Quant, the three most recent readings for SGMT's Common Equity are $102.5 million (Q1 2026), $111.4 million (Q4 2025), and $119.3 million (Q3 2025).